Evotec SE (EVO, $5.23) was a top loser over the last three months, falling -3 to $5.23 per share. A.I.dvisor analyzed 294 stocks in the Pharmaceuticals: Other Industry for the 3-month period ending April 24, 2024, and found that of them (5) exhibited an Uptrend while of them (4) demonstrated a Downtrend.